Patients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. To date, there are no US FDA-approved drug therapies that are designed to target Lp(a) with the goal of lowering the Lp(a) level in patients who have increased risk. The American College of Cardiology (ACC) has provided guidelines on how to use traditional lipid profiles to assess the risk of atherosclerotic cardiovascular disease (ASCVD); however, even with the emergence of statin add-on therapies such as ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, some populations with elevated Lp(a) biomarkers remain at an increased risk for cardiovascular (CV) disease. Residual CV risk has led researchers to inquire about how lowering Lp(a) can be used as a potential preventative therapy in reducing CV events. This review aims to present and discuss the current clinical and scientific evidence pertaining to pelacarsen.

与遗传相关的脂蛋白（a）[Lp（a）] 水平升高的患者患冠状动脉疾病、心脏病发作、中风和外周动脉疾病的风险更大。迄今为止，尚无美国 FDA 批准的药物疗法旨在针对 Lp(a) 以降低风险增加患者的 Lp(a) 水平为目标。美国心脏病学会 (ACC) 提供了有关如何使用传统血脂谱评估动脉粥样硬化性心血管疾病 (ASCVD) 风险的指南；然而，即使出现了他汀类药物附加疗法，如依折麦布和前蛋白转化酶枯草杆菌蛋白酶 / kexin 9 型 (PCSK9) 抑制剂，一些 Lp(a) 生物标志物升高的人群仍处于心血管 (CV) 疾病风险增加的境地。残余 CV 风险促使研究人员询问如何将降低 Lp(a) 用作减少 CV 事件的潜在预防疗法。本综述旨在介绍和讨论有关 pelacarsen 的当前临床和科学证据。